Durg Coated Balloon Angioplasty in Infrapopliteal Lesions

Recruiting

• Conditions: Peripheral Artery Disease; Chronic Limb Threatening Ischemia; Arteriosclerosis

• Registration Number: NCT05620095
• Lead Sponsor: Liyuan Hospital of Tongji Medical College, Huazhong University of Science and Technology

Brief Summary

This study is a multicenter observational study designed to evaluate the the effectiveness and safety of drug-coated balloon (DCB) angioplasty for below the knee arterial lesions in patients critical with Limb Threatening Ischemia (CLTI).

Detailed Description

Patients with critical limb ischemia (Rutherford category 4-5) and significant infrapopliteal lesions appropriate for angioplasty will be enrolled in this study. Subjects will be treated with the AcoArt drug coated balloon, then follow-up will be conducted at 1, 3, 6, 12 months after index procedure. Data on wound, ischemia, foot infection (WIfI) calcifications, clinical improvements, wound healing, freedom form target- lesion revascularization, patency of the target lesion and major adverse events will be collected.

Study Timeline

• Study Start: 2020-12-01
• Study First Submitted: 2022-11-09
• Study First Submitted QC: 2022-11-09
• Study First Posted: 2022-11-17
• Status Verified: 2024-01
• Last Update Submitted: 2024-03-02
• Last Update Posted: 2024-03-05
• Primary Completion: 2025-11-01
• Study Completion: 2026-11-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 1000

Inclusion Criteria

1. Rutherford grade 4-5.
2. Patients who understand the purpose of this study, volunteer to participate in the experiment, sign informed consent and are willing to follow up.
3. Single or sequential de novo or restenotic lesions (stenosis ≥ 70% diameter reduction or occlusion) in the infrapopliteal arteries >20 mm. Lesions should not extend beyond the ankle joint.
4. Successful wire crossing of the lesion. After the pre-dilation of the ordinary balloon, the angiography showed that there was continuous blood flow.
5. At least one of the infrapopliteal arteries received a drug-coated balloon.
6. For patients with aortoiliac artery disease and femoral-popliteal artery disease, after intravascular reconstruction, blood flow can be recanalized, and there is no residual stenosis of more than 50%.
7. In patients with lower extremity arterial thrombosis, after mechanical thrombectomy, percutaneous catheter thrombolysis, and thrombus removal, patients receiving blew the knee arterial drug balloon intervention.
8. Patients who have received DCB intervention for both lower limbs can be enrolled in the group according to the intracavitary treatment time.
9. Life expectancy> 24 months.

Exclusion Criteria

1. Blood flow was not successfully reestablished.
2. Patients with stroke, cerebral hemorrhage, gastrointestinal hemorrhage or myocardial infarction within 3 months before enrollment.
3. Patients who are known to be allergic to heparin, aspirin, other antiplatelet drugs, contrast agents, etc.
4. Patients who have participated in clinical trials of drugs or other medical devices that interfere with this clinical trial within the past 3 months.
5. Pregnant and lactating women.
6. Patients with Berg's disease.
7. Patients requiring major amputation based on preoperative evaluation of limb infection or severe ischemia

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary sustained clinical improvement at 12 months post-procedure	12 months	Primary sustained clinical improvement was defined as an upward shift on the Rutherford classification (Appendix) to a level of intermittent claudication without the need for repeated TLR in surviving patients without the need for unplanned amputation.
Freedom of major limb adverse events at 12 months post-procedure	12 months	Major limb adverse events were defined as the composite of clinically-driven target lesion revascularization (CD-TLR); unplanned, unavoidable major amputation of the index limb; and treatment caused death.

Secondary Outcome Measures

Name	Time	Method
Patency of the target lesions at 1 month, 3 months, 6 months and 12 months post-interventional	1 month, 3 months, 6 months, 12 months	Patency includes the absence of clinically driven target lesion revascularization and/or recurrent target lesion diameter stenosis ≥50% by imaging (e.g., invasive angiography or, most commonly, duplex ultrasonography).
Amputation free survival rate	1 month, 3 months, 6 months, 12 months	Amputation free survival rate after surgery.
Vascular quality of life questionnaire(VascuQol)	1 month, 3 months, 6 months, 12 months	The VascuQol was designed as a questionnaire containing five domains: pain (4 items), symptoms (4 items), activities (8 items), social (2 items), and emotional (7 items) to evaluate Health related quality of life (HRQL). Every item has seven response options, with scores ranging from 1 to 7. A total score is the sum of all 25 item scores divided by 25.And both the total score as well as the domain scores range from 1 (worst HRQL) to 7 (best HRQL).The lower the value, the poorer the quality of life.; 1 month, 3 months, 6 months, 12 months
Secondary sustained clinical improvement	1 month, 3 months, 6 months, 12 months	Percentage of participants that experienced a secondary sustained clinical improvement, specified as an improvement shift in the Rutherford classification of one class including the need for clinically driven TLR in amputation free surviving subjects.
Procedural success rate	72 hours	Procedural success for peripheral revascularization is defined as both technical success and absence of major adverse events (e.g., death, stroke, myocardial infarction, acute onset of limb ischemia, index bypass graft or treated segment thrombosis, and/or need for urgent/emergent vascular surgery) within 72 hours of the index procedure.
Freedom from clinically-driven target lesion revascularization(CD-TLR) rate at 1 month, 3 months, 6 months, 12 months post-procedure.	1 month, 3 months, 6 months, 12 months	Clinically driven target lesion revascularization is defined as target lesion revascularization performed due to target lesion diameter stenosis ≥50% and either evidence of clinical or functional ischemia (e.g., recurrent/progressive life-limiting intermittent claudication, claudication unresponsive to medical therapy, CLI) or recurrence of the clinical syndrome for which the initial procedure was performed.
Major adverse events at 1 month, 3 months, 6 months, 12 months post-procedure.	1 month, 3 months, 6 months, 12 months	Death, unplanned major amputation of the target limb, and CD-TLR were defined as a major adverse event.
Primary sustained clinical improvement	1 month, 3 months, 6 months	Percentage of participants that experienced primary sustained clinical improvement, specified as an improvement shift in the Rutherford classification of one class in amputation free, clinically driven target lesion revascularization (TLR) free surviving subjects.
Wound healing rate	1 month, 3 months, 6 months, 12 months	Wound healing in patients with Rutherford grade 5.

Trial Locations

Locations (10)

Xuanwu Hospital Capital Medical University; 🇨🇳 Beijing, Beijing, China

the second Affiliated Hospital of Medical College of Suzhou University; 🇨🇳 Suzhou, Jiangsu, China

Zibo Feng; 🇨🇳 Wuhan, Hubei, China

Qingdao Haici hospital affiliated to Qingdao University; 🇨🇳 Qingdao, Shandong, China

Huashan Hospital, Fudan University; 🇨🇳 Shanghai, Shanghai, China

Hangzhou First People's hospital of Medical College of Zhejiang University; 🇨🇳 Hangzhou, Zhejiang, China

the First Affiliated hospital of Medicine College of Zhejiang University; 🇨🇳 Hangzhou, Zhejiang, China

Renji Hospital of Shanghai Jiaotong University; 🇨🇳 Shanghai, Shanghai, China

Zhongshan Hospital of Fudan University; 🇨🇳 Shanghai, Shanghai, China

Hospital of Chengdu University of Traditional Chinese Medicine; 🇨🇳 Chengdu, Sichuan, China